Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Davies, Kurtis D ^a   Mahale, Sakshi ^a   Astling, David P ^a   Aisner, Dara L ^a   Le, Anh T ^a   Hinz, Trista K ^b   Vaishnavi, Aria ^a   Bunn Jr , Paul A ^a   Heasley, Lynn E ^b   Tan, Aik Choon ^a   Camidge, D Ross ^a   Varella Garcia, Marileila ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; NVP TAE 684; PEMETREXED; PROTEIN ROS1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAE 684; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CASE REPORT; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84892655145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082236     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Oxnard GR, Binder A, Janne PA (2013) New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31: 1097-1104.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
5. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774.
6. Camidge DR, Doebele RC (2012) Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 9: 268-277.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394.
8. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075.
9. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
10. Hammerman PS, Janne PA, Johnson BE (2009) Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15: 7502-7509.
11. Ohashi K, Maruvka YE, Michor F, Pao W (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31: 1070-1080.
12. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739.
13. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, et al. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108: 7535-7540.
14. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, et al. (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18: 1472-1482.
15. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, et al. (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051-6060.
16. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4: 120ra117.
17. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501.
18. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
20. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
21. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, et al. (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109: E2127-2133.
22. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, et al. (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2: 934-947.
23. Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, et al. (2013) Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 73: 834-843.
24. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, et al. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2: e39.
25. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283.
26. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509.
27. Davies KD, Doebele RC (2013) Molecular Pathways: ROS1 Fusion Proteins in Cancer. Clin Cancer Res 19: 4040-4045.
28. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, et al. (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18: 4570-4579.
29. Ou SH, Bang YJ, Camidge DR, Riely GJ, Salgia R, et al. (2013) Efficacy and Safety of Crizotinib in Patients with Advanced ROS1-rearranged Non-small Cell Lung Cancer. J Clin Oncol 31: (suppl; abstr 8032PD).
30. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, et al. (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368: 2395-2401.
31. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870.
32. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
33. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, et al. (2006) Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12: 7117-7125.
34. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, et al. (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250.
35. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
36. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
37. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, et al. (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465-472.
38. Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, et al. (2013) The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis 2: e43.
39. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, et al. (2012) Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 18: 3592-3602.
40. Kim S, Kim TM, Kim DW, Go H, Keam B, et al. (2013) Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 8: 415-422.
41. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24: 32-91.
42. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, et al. (1998) Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21: 308-319.
43. Oie HK, Russell EK, Carney DN, Gazdar AF (1996) Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl 24: 24-31.